Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 10.75
0.186 %
$ 979 M
Market Cap
-7.62
P/E
Price Target
Average
176.41%
Revenue Forecast
Estimate
10.82%
EBIT
Estimate
9.96%
Net Income
Estimate
30.67%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Myriad Genetics, Inc.
Wall Street analysts predict an average 1-year price target for MYGN of $29.7 , with forecasts ranging from
a
low of
$21 to a high of $35 .
MYGN Lowest Price Target
Wall Street Target
21 USD
95.35%
MYGN Average Price Target
Wall Street Target
29.7 USD
176.41%
MYGN Highest Price Target
Wall Street Target
35 USD
225.58%
REVENUE FORECAST
Revenue Forecast Chart MYGN
EBIT FORECAST
EBIT Forecast Chart MYGN
NET INCOME FORECAST
Net Income Chart MYGN